Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Kaizhou Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0844-826X; OpenAlex author ID A5109350335. Sources: OpenAlex.

Their work

Papers
52 (first author 7, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

2015: 4 papers · 2016: 6 papers · 2017: 6 papers · 2018: 5 papers · 2019: 4 papers · 2020: 7 papers · 2021: 2 papers · 2022: 5 papers · 2023: 5 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 50 of 52

  1. Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. Co-author DOI 10.1007/s00535-026-02468-4↗
  2. Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic. Co-author DOI 10.3389/fimmu.2026.1782960↗
  3. Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2025.111048↗
  4. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  5. Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. Co-author DOI 10.1186/s13046-025-03563-9↗
  6. The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2024.09.032↗
  7. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Last author DOI 10.1038/s41419-024-06589-7↗
  8. Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway. First author DOI 10.3724/abbs.2023286↗
  9. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
  10. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2023.216411↗
  11. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Co-author DOI 10.1038/s41419-023-06313-x↗
  12. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
  13. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Last author DOI 10.3724/abbs.2023045↗
  14. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. First author DOI 10.1016/j.canlet.2022.01.026↗
  15. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. First author DOI 10.1016/j.ebiom.2022.104016↗
  16. Body Composition and Response and Outcome of Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1080/01635581.2020.1870704↗
  17. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.956984↗
  18. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. Co-author DOI 10.3724/abbs.2022015↗
  19. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. First author DOI 10.1016/j.bbcan.2020.188409↗
  20. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  21. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.2895↗
  22. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  23. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  24. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  25. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  26. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  27. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  28. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cance… Co-author DOI 10.1002/cam4.2463↗
  29. Kras G12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.013↗
  30. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  31. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗
  32. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-018-2235-8↗
  33. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.017↗
  34. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  35. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001073↗
  36. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗
  37. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Co-author DOI 10.1002/ijc.30650↗
  38. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  39. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  40. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. First author DOI 10.1245/s10434-016-5579-3↗
  41. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Co-author DOI 10.3892/ijo.2017.4032↗
  42. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. First author DOI 10.3892/ol.2016.5501↗
  43. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  44. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2016.09.007↗
  45. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  46. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancr… Co-author DOI 10.1158/1078-0432.ccr-15-2380↗
  47. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms17071090↗
  48. Critical role of oncogenic KRAS in pancreatic cancer (Review). Co-author DOI 10.3892/mmr.2016.5196↗
  49. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.03.012↗
  50. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Co-author DOI 10.1245/s10434-014-4021-y↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 49 shared papers, 2015–2026 · strength 5.51
  2. Chen Liu · 37 shared papers, 2015–2025 · strength 3.32
  3. Weiding Wu · 16 shared papers, 2021–2026 · strength 3.09
  4. Long‐Yun Ye · 14 shared papers, 2022–2026 · strength 2.85
  5. Guopei Luo · 32 shared papers, 2015–2025 · strength 2.64
  6. Qinglin Fei · 10 shared papers, 2022–2026 · strength 1.95
  7. He Cheng · 21 shared papers, 2016–2022 · strength 1.85
  8. Quanxing Ni · 25 shared papers, 2015–2021 · strength 1.82
  9. Zhiyao Fan · 16 shared papers, 2018–2021 · strength 1.52
  10. Saimeng Shi · 8 shared papers, 2022–2025 · strength 1.51
  11. Yitao Gong · 11 shared papers, 2019–2021 · strength 1.17
  12. Jin Xu · 17 shared papers, 2015–2025 · strength 1.16
  13. Duancheng Guo · 5 shared papers, 2023–2025 · strength 1.13
  14. Tianjiao Li · 6 shared papers, 2022–2024 · strength 1.00
  15. Liang Liu · 14 shared papers, 2015–2022 · strength 0.91
  16. Huiru Zhang · 5 shared papers, 2022–2024 · strength 0.91
  17. Yunzhen Qian · 8 shared papers, 2020–2021 · strength 0.87
  18. Chao Yang · 10 shared papers, 2018–2020 · strength 0.84
  19. Meng Guo · 14 shared papers, 2015–2018 · strength 0.83
  20. Zhenyu Liao · 5 shared papers, 2022–2023 · strength 0.75
  21. Zhiwen Xiao · 8 shared papers, 2015–2022 · strength 0.68
  22. Jiang Long · 11 shared papers, 2015–2018 · strength 0.65
  23. Kun Fan · 7 shared papers, 2018–2020 · strength 0.60
  24. Weiding Wu · 2 shared papers, 2025–2026 · strength 0.59
  25. Xuan Lin · 3 shared papers, 2022–2023 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.